Cogstate: Dementia clinical trial with Lewy bodies used digital assessments and data quality services from Cogstate to support assessment of Neflamapimod


One study showed that Neflamapimod improved cognition, motor function and Progression of Dementia Compared to Placebo

Neuroscience technology company Cogstate Ltd (ASX.CGS) has announced that its digital cognitive assessments are part of the primary endpoint of the AscenD-LB study, a Phase 2 clinical trial in body-to-body dementia. Lewy (DLB) led by EIP Pharma Inc. The company announced the final results of the trial, which demonstrated that treatment with neflamapimod resulted in a significant improvement compared to placebo in terms of cognition, functional mobility and progression of dementia in patients with DCL.

DCL is the second most common form of dementia and there is currently no treatment available for this disease. The results of the AcendD-LB trial represent a possible breakthrough in the development of a therapeutic candidate for people affected by CDL worldwide.

The main objective of the AscenD-LB study was to assess the effect of neflamapimod, an experimental oral drug, on cognition, as measured by Cogstate digital assessments (Detection, Identification, One Card Learning, One Back, Verbal Fluency and Category Fluency).

Secondary endpoints included Neuropsychiatric Inventory (NPI), Timed Up and Go Test (TUG), and Clinical Dementia Rating Scale (CDR-SB), for which Cogstate provided comprehensive testing services. data quality, including training of assessors and monitoring.

“For years, neurodegenerative disease treatment strategies have sought to support cholinergic neurotransmission in the basal forebrain,” said Dr. Paul Maruff, Cogstate innovation director. “This is a remarkable finding that for people with treatment for DCL with the drug neflamapimod offered to restore the function of cholinergic neurons in the basal forebrain although inhibition of p38α kinase has resulted in a substantial improvement in measures of attentional function, as shown by the Cogstate battery. This success reflects innovation and precision in the preclinical development and clinical translation of the drug. It also provides a solid basis for the further development of neflamapimod as a treatment for DLB Congratulations to the EIP Pharma team and to all the patients, caregivers and clinicians who contributed to this trial. ”

Read the EIP Pharma press release here:

About Cogstate Ltd.
Cogstate Ltd. (ASX: CGS) is a neuroscience technology company focused on optimizing brain health assessments to advance new drug development and enable earlier clinical knowledge in healthcare. Cogstate is the pioneer of fast, reliable and highly sensitive digital cognitive testing technologies, and provides data quality services for clinical outcome evaluations that combine scientific knowledge, innovative operational approaches and advanced analytics. For over 20 years, Cogstate has proudly supported the cutting-edge research needs of biopharmaceutical companies and academic institutions as well as the clinical care needs of physicians and patients around the world.

Media inquiries
Rachel Colitis – [email protected]

Back to news


CogState Ltd. published this content on November 29, 2021 and is solely responsible for the information it contains. Distributed by Public, unedited and unmodified, on November 29, 2021 07:10:02 PM UTC.


Comments are closed.